Ionizing radiation potentiates the antitumor efficacy of oncolytic herpes simplex virus G207 by upregulating ribonucleotide reductase

This publication has 16 references indexed in Scilit:

• Activation ofGadd34 by diverse apoptotic signals and suppression of its growth inhibitory effects by apoptotic inhibitors
  International Journal of Cancer, 2001
• Ionizing Radiation Does Not Alter the Antitumor Activity of Herpes Simplex Virus Vector G207 in Subcutaneous Tumor Models of Human and Murine Prostate Cancer
  Neoplasia, 2001
• Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma
  Gene Therapy, 2000
• Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial
  Gene Therapy, 2000
• Replication-Competent Herpes Simplex Virus Vector G207 and Cisplatin Combination Therapy for Head and Neck Squamous Cell Carcinoma
  Neoplasia, 1999
• Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: a new paradigm for destruction of therapeutically intractable tumors
  Gene Therapy, 1998
• Mammalian GADD34, an Apoptosis- and DNA Damage-inducible Gene
  Journal of Biological Chemistry, 1997
• Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas
  Nature Medicine, 1995
• Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma.
  Proceedings of the National Academy of Sciences, 1995
• The gamma 1(34.5) gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programed cell death in neuronal cells.
  Proceedings of the National Academy of Sciences, 1992